On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million. Testing revenue was $107.0 million, an increase of 31%, driven by the strong performance of our Decipher Prostate and Afirma tests. Total test volume grew to 39,023, an increase of 23% compared to the second quarter of 2023. During the quarter, the company achieved a record Decipher Prostate test volume of close to 19,900 tests, driven by recently updated NCCN pros ...

分组1 - Veracyte reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and compared to a loss of $0.12 per share a year ago, representing an earnings surprise of 1,100% [1] - The company achieved revenues of $114.43 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 14.04%, and up from $90.32 million year-over-year [2] - Veracyte has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 23.7% since the beginning of the year, while the S&P 500 gained 8.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $101.22 million, and for the current fiscal year, it is -$0.05 on revenues of $406.07 million [7] - The Medical - Instruments industry, to which Veracyte belongs, is currently in the top 40% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

This molecular diagnostic company is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents a year-over-year change of +75%. Revenues are expected to be $100.34 million, up 11.1% from the year-ago quarter. For Veracyte, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on VCYT going forward ...

But what's the best way to find the right combination of stocks? Because funding things like your retirement, your kids' college tuition, or your short- and long-term savings goals will definitely require significant returns. What is the Zacks Rank? Agreement is the extent to which all brokerage analysts are revising their earnings estimates in the same direction. The greater the percentage of analysts revising their estimates higher, the better chance the stock will outperform. Upside is the difference bet ...

Inventory Turnover, Receivables Turnover, Asset Utilization, and Operating Margin greater than the industry average Veracyte (VCYT) is a global diagnostics company that provides clinicians with valuable insights to diagnose and treat cancer. VCYT has an average four-quarter earnings surprise of 59.7%. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, ...

A month has gone by since the last earnings report for Veracyte (VCYT) . Shares have added about 8.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Veracyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Veracyte's Q1 Loss Lower Than Expected,'24 Sales View Up ...

Veracyte (VCYT) closed the last trading session at $21.45, gaining 9.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $29.83 indicates a 39.1% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $5.71. While the lowest estimate of $21 indicates a 2.1% decline from the current price level, the most optimistic analyst expects the ...

Over the past four weeks, VCYT has gained 9.6%. The company is currently ranked a Zacks Rank #1 (Strong Buy), another strong indication the stock could move even higher. Once investors consider VCYT's positive earnings estimate revisions, the bullish case only solidifies. No estimate has gone lower in the past two months for the current fiscal year, compared to 2 higher, and the consensus estimate has increased as well. Given this move in earnings estimate revisions and the positive technical factor, invest ...

Irrespective of market conditions, companies with favorable efficiency levels are more likely to be investors' choices. The reason is that a company with a favorable efficiency level is expected to offer impressive returns as it is believed to be positively correlated to its price performance. Efficiency ratio is an indication of a company's financial health. It analyzes how efficiently a company uses its assets and liabilities internally. However, at times it becomes difficult to measure the efficiency lev ...

Veracyte, Inc. (VCYT) , a leading name in cancer diagnostics, is set to showcase compelling data from three studies demonstrating the capabilities of its Afirma GRID (Genomic Resource for Intelligent Discovery) tool at ENDO 2024 from Jun 1-4. These findings promise to enhance the personalization of thyroid cancer treatment, marking a significant step forward in the molecular testing landscape. By enhancing the depth and accuracy of molecular testing, Veracyte's Afirma GRID tool is poised to play a crucial r ...